Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 7, 2009, Pages 1010-1016

  Bagur, Rodrigo ^a   Bertrand, Olivier F ^a   Rodés Cabau, Josep ^a   Larose, Éric ^a   Rinfret, Stéphane ^a   Nguyen, Can M ^a   Noel, Bernard ^a   De Larochellière, Robert ^a   Poirier, Paul ^a   Costerousse, Olivier ^a   Roy, Louis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Abciximab; Bolus; Platelets; Stent; Thrombosis; Transradial

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ADVERSE OUTCOME; AGE; ARTICLE; BOLUS INJECTION; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DIABETES MELLITUS; DRUG INFUSION; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TRANSRADIAL CORONARY STENTING; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, PARENTERAL; INJECTIONS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RADIAL ARTERY; RISK ASSESSMENT; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 72249093228     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22235     Document Type: Article

References (26)

1. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy. N Engl J Med 1998;339:436-443.
2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med 1998;338:1488-1497.
3. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial. Lancet 2000;356:2037-2044.
4. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, Delucca PT, Dibattiste PM. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887. (Pubitemid 32564900)
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-961
6. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997;278:479-484.
7. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6. (Pubitemid 34775153)
8. Mehta SR, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:(4 Suppl S)79S-88S. (Pubitemid 36223351)
9. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533. (Pubitemid 32772726)
10. Steinhubl SR, Berger PB, Mann JT, Fry ET, Delago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420. (Pubitemid 35340537)
11. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972. (Pubitemid 36258718)
12. Bertrand OF, De Larochelliere R, Rodes-Cabau J, Proulx G, Gleeton O, Nguyen CM, Dery JP, Barbeau G, Noel B, Larose E. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114:2636-2643. (Pubitemid 44967347)
13. Bertrand OF, Rodes-Cabau J, Larose E, Nguyen CM, Roy L, Dery JP, Courtis J, Nault I, Poirier P, Costerousse O. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the randomized early discharge after transradial stenting of coronary arteries (EASY) study. Am Heart J 2008;156:135-140.
14. Bertrand OF, Rodes-Cabau J, Larose E, Proulx G, Gleeton O, Nguyen CM, Nault I, Roy L, Poirier P, Costerousse O. Early and late outcomes in patients excluded from same-day home discharge after transradial stenting and maximal antiplatelet therapy. Catheter Cardiovasc Interv 2008;72:619-625.
15. Mangin L, Bertrand OF, De La Rochelliere R, Proulx G, Lemay R, Barbeau G, Gleeton O, Rodes-Cabau J, Nguyen CM, Roy L. The transulnar approach for coronary intervention: A safe alternative to transradial approach in selected patients. J Invasive Cardiol 2005;17:77-79. (Pubitemid 41724724)
16. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American college of cardiology task force on clinical data standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114-2130. (Pubitemid 33116592)
17. Bertrand OF, Larose E, De Larochelliere R, Proulx G, Nguyen CM, Dery JP, Gleeton O, Barbeau G, Noel B, Rouleau J. Out-patient percutaneous coronary intervention: Ready for prime time? Can J Cardiol 2007;23:(Suppl B)58B-66B.
18. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials. Am Heart J 2009;157:132-140.
19. Rao SV, Ou F, Wang TY, Roe MT, Brindis RG, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention. J Am Coll Cardiol Intv 2008;1:379-386.
20. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-1115. (Pubitemid 30206882)
21. Fischell TA, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: A safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18:487-491. (Pubitemid 44497339)
22. Kini AS, Chen VH, Krishnan P, Lee P, Kim MC, Mares A, Suleman J, Moreno PR, Sharma SK. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2008;156:513-519.
23. Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol 2008;20:53-58. (Pubitemid 351271441)
24. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-526. (Pubitemid 44704515)
25. Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. Catheter Cardiovasc Interv 2009;73:214-221.
26. Bertrand OF, Larose E, Rodes-Cabau J, Gleeton O, Taillon I, Roy L, Poirier P, Costerousse O, Larochelliere RD. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J 2009;157:164-169.